Valneva SE Sponsored ADR (NASDAQ:VALN) Stock Short Interest Drops 75.0%

Valneva SE Sponsored ADR (NASDAQ:VALN) was the recipient of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 47,986 shares, a decrease of 75.0% from the October 15th total of 191,916 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 23,384 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VALN. Weiss Ratings raised Valneva from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. TD Cowen began coverage on Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Valneva currently has an average rating of “Reduce” and an average target price of $9.30.

Valneva Price Performance

Shares of NASDAQ:VALN opened at $5.74 on Friday. The firm has a market capitalization of $546.01 million, a price-to-earnings ratio of -2.72 and a beta of 1.37. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The business’s 50 day simple moving average is $6.00 and its 200-day simple moving average is $6.68. Valneva has a 12 month low of $4.75 and a 12 month high of $12.18.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The firm had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. As a group, equities analysts forecast that Valneva will post -1.27 earnings per share for the current fiscal year.

About Valneva

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.